Angel News

Angel News

Back to Homepage

22nd November 2019

Beechbrook Capital’s Ireland SME fund completes first investment

Beechbrook Capital, the leading SME private debt fund lender, has appointed Conor Molloy as chairman of its new Irish SME fund which has made its first investment in the Republic of Ireland. Beechbrook Capital Ireland SME I is providing a €7.5 million finance package for Bio-Medical Research Limited (BMR), a world leader in electrical muscle stimulation technology for the fitness and wellness sector.


13th November 2019

Biotherapy secures £3 million investment from Foresight

Foresight Group has made a £3 million investment into Biotherapy Services Limited, a biopharmaceutical company specialising in regenerative medicine for the treatment of complex wounds.  One of its products is currently undergoing a clinical trial for treating chronic diabetic foot ulcers (DFUs).  

13th November 2019

Visionable raises £9.1m as it looks to the future of healthcare communication

Visionable, the healthcare technology company providing a single video collaboration platform that enables clinicians to deliver better patient care, has raised £9.1m, following a 50% oversubscribed funding round, valuing the company at £47.6m.

Led by West Hill Capital, which has a reputation for backing British companies that are making a real difference, the funding round signals the next stage in the growth of the British health start-up. Having seen a busy 2019, which involved the trial of a connected ambulance with O2, the latest funds will allow Visionable to build on this momentum and continue to have a positive impact globally on the lives of patients and clinicians.

8th November 2019

University of Birmingham spin-out Linear Diagnostics secures £2m for diagnostic technology

Birmingham-based Linear Diagnostics Limited (LDL) has secured £2m of investment from MEIF and other investors to develop new platform technology for medical diagnostic testing.

8th November 2019

Swansea based Medical Connections completes management buy-out

Swansea based Medical Connections Limited has successfully completed a management buy-out.

The medical imaging software toolkit company was founded by the late Doctor David Harvey in 1998. As a consultant radiologist, he was passionate about the development of healthcare IT to deliver better patient care.  The Company is a well-established medical imaging toolkit provider and has been recognised as a global leader in facilitating the development of healthcare IT systems to promote interoperability.

7th November 2019

Flarin Holdings completes first round of fundraising for revolutionary drug

Flarin Holdings Limited has completed its first round of fund-raising by IW Capital. Flarin Holdings was recently demerged from Infirst Healthcare Limited in order to provide greater focus on the rapid commercialisation of Flarin.  Flarin is a unique and patent protected lipid formulated ibuprofen which at a dose of 1200 mg/day has shown to be as effective as 2400mg/day of standard liquid ibuprofen capsules in patients with acute joint pain. Flarin’s unique lipid formulation also helps to shield the stomach from damage.

6th November 2019

Oxford University biotech spin-out raises over £2M to combat resistance to antibiotics

Oxford Drug Design Limited (ODD), a biotechnology company with a proprietary computational and machine learning platform, has raised a combined £2.2M in funding from the Angel CoFund (ACF), o2h Ventures and other new investors, and grant funding from the UK Department of Health and Social Care (DHSC)'s UK-China research competition. This brings the firm’s total amount of grant and equity funding raised in 2019 to over £9M.

5th November 2019

Medopad secures $25m funding for ambitious digital medicine innovations

Medopad, a fast-growing healthtech AI startup headquartered in London, has earned investment in a funding round led by Leaps by Bayer in to further develop its digital health platform. The investment brings Medopad’s total amount raised to over $50M. The company will use the new funds to fuel clinical studies, including digital biomarker discovery, creation of digital therapeutics (DTx), technology development, geographic expansion and commercial growth through strategic collaborations.



29th October 2019

Impel Healthcare Catalysts announces first deal

New investment company Impel Healthcare Catalysts has announced its first deal by acquiring a majority stake in pioneering ostomy company Trio Healthcare. 


This is the first major deal for Knutsford-based Impel, which was launched earlier this month by entrepreneurs Richard Anderson and Spencer Kerry – previously part of the management team behind Crawford Healthcare - to be a catalyst for innovation and growth in the healthcare sector.

23rd October 2019

Ex-Crawford execs launch healthcare investment company

Healthcare entrepreneurs Richard Anderson and Spencer Kerry have launched Impel Healthcare Catalysts, an investment company designed to be a catalyst for innovation and growth in the healthcare sector. 

Headquartered in Knutsford, Impel will provide growth capital along with strategic expertise, primarily to businesses based in the UK, making use of the management team’s broad healthcare knowledge and track record to deliver rapid growth and strong returns. It will typically invest in companies with enterprise values up to £50m initially, and also has the capability to co-invest with other debt and equity funders. 

17th October 2019

New ‘eyes in the skies’ as med-tech firm secures investment to scale in-flight medical monitoring

MIME Technologies, a med-tech spin-out from the University of Aberdeen, has raised a combined £255,000 from first round investment and a Scottish Enterprise grant.

Designed to revolutionise the support given to cabin crew during in-flight medical events, MIME Technologies’ innovative product can monitor a passenger’s vital signs while communicating with clinicians on the ground.

15th October 2019

Cambridge medtech firm raises $16m Series A to advance life-saving cell therapies

Mogrify Ltd, a UK company aiming to transform the development of life-saving cell therapies, has announced the initial close of its Series A funding. The Company raised $16 million USD in this round, bringing the total investment to over $20 million USD to date. The funding will support internal cell therapy programs, and the development and out-license of novel IP relating to cell conversions of broad therapeutic interest. Mogrify is also actively recruiting, and will increase headcount to 60 scientific, operational and commercial staff located at its state-of-the-art facility on Cambridge Science Park.


PREVIOUSItems 12 of 186NEXT

Back to Homepage